nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A boost for personalised medicine
|
The Lancet Haematology, |
|
2015 |
2 |
3 |
p. e82- 1 p. |
artikel |
2 |
First-line therapy for CML: decisions, decisions
|
Davies, Jeff |
|
2015 |
2 |
3 |
p. e89-e90 nvt p. |
artikel |
3 |
HSCT: navigating the journey ahead
|
Copelan, Edward |
|
2015 |
2 |
3 |
p. e83-e84 nvt p. |
artikel |
4 |
Is another antibody conjugate against ALL needed?
|
Wayne, Alan S |
|
2015 |
2 |
3 |
p. e87-e88 nvt p. |
artikel |
5 |
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
|
Jain, Preetesh |
|
2015 |
2 |
3 |
p. e118-e128 nvt p. |
artikel |
6 |
One million haemopoietic stem-cell transplants: a retrospective observational study
|
Gratwohl, Alois |
|
2015 |
2 |
3 |
p. e91-e100 nvt p. |
artikel |
7 |
Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial
|
Hassall, Oliver W |
|
2015 |
2 |
3 |
p. e101-e107 nvt p. |
artikel |
8 |
Umbilical cord blood transfusions in low-income countries
|
Gluckman, Eliane |
|
2015 |
2 |
3 |
p. e85-e86 nvt p. |
artikel |
9 |
90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
|
Chevallier, Patrice |
|
2015 |
2 |
3 |
p. e108-e117 nvt p. |
artikel |